Researchers Uncover Gene Signature That May Personalize Rx for Rare Leukemia Syndrome | GenomeWeb
Researchers at St. Vincent’s Comprehensive Cancer Center have identified a new gene signature that may help doctors determine which pre-leukemia patients will benefit from treatment with Celgene's myelodysplastic syndrome drug Revlimid (lenalidomide).
Although the findings need to be replicated, researchers hope eventually to develop a “simple diagnostic” for this indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.